Possibility?
|
1
|
Resverlogix Corp.
|
May 07, 2024 09:30AM
|
Re: Lu stepping down
|
3
|
Resverlogix Corp.
|
Apr 25, 2024 03:01PM
|
Re: Lu stepping down
|
1
|
Resverlogix Corp.
|
Apr 25, 2024 02:15PM
|
Re: Report Of Exempt Distribution.
|
2
|
Zenith Epigenetics
|
Apr 17, 2024 07:10PM
|
Re: Report Of Exempt Distribution.
|
4
|
Zenith Epigenetics
|
Apr 17, 2024 03:58PM
|
Re: Lu stepping down
|
5
|
Resverlogix Corp.
|
Feb 22, 2024 06:12PM
|
Re: Lu stepping down
|
1
|
Resverlogix Corp.
|
Feb 22, 2024 02:24PM
|
Re: Lu stepping down
|
2
|
Resverlogix Corp.
|
Feb 22, 2024 02:06PM
|
Covid study
|
10
|
Resverlogix Corp.
|
Feb 12, 2024 01:14PM
|
Re: ZHCLF
|
1
|
Zenith Epigenetics
|
Jan 30, 2024 02:24PM
|
Re: Epigenetics market size
|
1
|
Zenith Epigenetics
|
Jan 22, 2024 02:46PM
|
Re: Long Covid
|
6
|
Resverlogix Corp.
|
Jan 22, 2024 02:21PM
|
Re: Letting them ride ,
|
4
|
Resverlogix Corp.
|
Jan 02, 2024 04:47PM
|
Re: Bad idea?
|
5
|
Resverlogix Corp.
|
Dec 18, 2023 04:08PM
|
Re: Zenith AGM
|
3
|
Zenith Epigenetics
|
Nov 22, 2023 02:03PM
|
Re: Sent this to IR
|
5
|
Resverlogix Corp.
|
Nov 16, 2023 04:52PM
|
Re: The crick didn’t rise, here’s the presentation, finally!
|
6
|
Zenith Epigenetics
|
Oct 29, 2023 09:37PM
|
Re: The crick didn’t rise, here’s the presentation, finally!
|
3
|
Zenith Epigenetics
|
Oct 28, 2023 11:44AM
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
1
|
Resverlogix Corp.
|
Oct 04, 2023 01:27PM
|
Re: Recent publications:
|
6
|
Resverlogix Corp.
|
Sep 27, 2023 02:25PM
|